Lab Genomics

Sourcing is built around the bio-repository in Seongnam. Academic collaborators at Korean university hospitals refer startups seeking validation cohorts, while the Foster City office converts Bay Area founders who need access to Asian phenotypic data for clinical trials or algorithm training. The firm also scans the commercial sequencing ecosystem in Asia for infrastructure plays that sit upstream of the data-generation curve.

Lab Genomics makes direct equity investments and also structures data-licensing arrangements where the bio-bank is contributed as in-kind value. The firm has not publicly disclosed any fund-of-funds commitments, operating instead as a direct investor at the Seed through Series B stages in biotechnology and digital health.

The firm does not invest in therapeutics companies that require expensive, multi-year FDA clinical trials outside its data partnerships. It also avoids direct-to-consumer genetic testing models with unproven reimbursement pathways. The focus remains on the picks-and-shovels layer of genomic computation rather than long-duration drug development or retail health apps.

The firm maintains research collaboration agreements with several university-hospital systems in the Seoul metropolitan area, with the bio-bank drawing longitudinal samples and phenotypic data from these institutions under formal data-governance protocols. Lab Genomics is not a subsidiary of or controlled by any single hospital, operating as an independent venture platform that licenses data access in exchange for shared research capabilities.